CompletedPhase 3

Hyper- and Hypokalemic Periodic Paralysis Study

United States71 participantsStarted 2007-06

Plain-language summary

The purpose of this study is to compare Dichlorphenamide with placebo (an inactive substance) for prevention of episodes and for improvement of strength in hyperkalemic (HYP) and hypokalemic (HOP) periodic paralysis. This study will also look at the long-term effects of Dichlorphenamide in periodic paralysis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Prolonged QT interval or complex ventricular ectopy between attacks
✕. Distinctive physical features (2 of the following 5)
✕. Low set ears
✕. Short stature
✕. Hypo-/micrognathia
✕. Clinodactyly
✕. Hypo-/hypertelorism
✕. KIR 2.1 gene mutation

What they're measuring

HYP Attack Rate

Timeframe: 8 weeks

HOP Attack Rate

Timeframe: 8 weeks

Trial details

NCT IDNCT00494507

SponsorUniversity of Rochester

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-04

Results submitted2014-04-30

View on ClinicalTrials.gov More Hyperkalemic Periodic Paralysis trials